Quoin (QNRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$5.4M

Net income growth (year over year)

−45.32%

Net margin

—

Return on equity

−575.73%

EPS (trailing twelve months)

−$508.87

Book value per share

$1.96

P/E (trailing twelve months)

—

Price to book

5.07

Debt to assets

67.14%

Payout ratio

—

Dividend yield

—

Company profile

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

• How do I buy stock in Quoin (QNRX)?

  QNRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.